ArticleClinical epigenetics2025
Deciphering the methylation landscape of long noncoding RNAs in hepatocellular carcinoma: a focus on LINC00942.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundConduct a comprehensive genome-wide methylomic analysis of long noncoding RNA (lncRNA) genes in hepatocellular carcinoma (HCC) and identify specific lncRNAs for subsequent functional validation.
methodsWe conducted a methylation microarray analysis on 11 HCC samples alongside adjacent non-tumor tissue specimens. This analysis was integrated with The Cancer Genome Atlas data and the Gene Expression Omnibus for a comprehensive methylomic evaluation. Following this, a LASSO retrospective analysis was employed to develop a prognostic model for HCC, utilizing the methylation levels of specific lncRNA genes. Ultimately, LINC00942 was identified as a significant candidate within the model, and its biological effects in HCC cells were investigated through both in vitro and in vivo experiments. Additionally, potential downstream target genes of LINC00942 were elucidated using western blot analysis.
resultsGenome-wide hypomethylation and CpG island hypermethylation within lncRNA genes were observed in HCC. Furthermore, a prognostic model utilizing the methylation levels of five specific lncRNA genes has demonstrated high accuracy in predicting the prognosis of patients diagnosed with HCC. LINC00942, an identified lncRNA within the model, exhibits hypomethylation and elevated expression levels in HCC. Methylation within the promoter region has been shown to suppress its expression in HCC cells. Both in vivo and in vitro studies have demonstrated that the silencing of LINC00942 leads to a decrease in the proliferation, migration, and invasion of HCC cells. Flow cytometry analyses revealed a significant increase in cell cycle arrest and apoptosis in HCC cells following the knockdown of LINC00942. The result of western blot indicates that cyclin D1, CDK2, and BAX are probable downstream target molecules of LINC00942.
conclusionsA substantial quantity of lncRNAs is transcriptionally modulated by methylation in HCC. The demethylation of LINC00942 within its promoter region facilitates the upregulation of LINC00942 expression, thereby contributing to its function as an oncogene in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.